Compare DuPont de Nemours Inc (DD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs State Street SPDR S&P Biotech ETF — how do they compare? DuPont de Nemours Inc trades at $130.51 (market cap $17.89B), while State Street SPDR S&P Biotech ETF trades at $153.82 (market cap $10.11B). The key difference: DuPont de Nemours Inc is the larger of the two by market cap, and DuPont de Nemours Inc pays a 1.81% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DD | XBI | |
|---|---|---|
Market Cap | $17.89B | $10.11B |
Volume | 816,409 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $154.59 | $169.55 |
52-Week Low | $92.49 | $104.99 |
Typical Hold Time | 89 Days | 38 Days |
Enterprise Value | $19.28B | — |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $130.53, down 0.42% on the day, with a neutral technical signal and bearish moving average trend. The company reported a net loss of $779 million in 2025 despite beating EPS estimates in recent quarters, with revenue declining to $6.85 billion. Analyst consensus is bullish with 59% buy ratings, though the consensus price target of $95 is below the current price. Recent news highlights innovation in Tyvek materials and digital tools, alongside legal settlements over PFAS contamination.
The outlook is mixed: strong analyst support and product innovation offer upside, but recent profitability challenges, high P/E ratio, and legal liabilities pose risks. Earnings growth and margin recovery are critical for sustaining investor confidence amid volatile cash flows and competitive pressures.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
